MicroPort® NeuroTech™ Completes the First Commercial Implantation of Tubridge™ Flow Diverter in Argentina

Buenos Aires, Argentina, 28 March, 2024 — MicroPort® NeuroTech™ recently completed the first commercial implantation of Tubridge™ Flow Diverter (Tubridge™) in Argentina. The Tubridge™'s exceptional performance recieved high praise from the surgical team.

The surgery was performed by Dr. Carlos Miranda and his team at Sagrado Corazon Hospital. The 68-year-old patient was diagnosed preoperatively with a fusiform basilar artery aneurysm. Given the patient's large vessel size and the wide neck of the fusiform aneurysm, a traditional Flow Diverter was inadequate. Nevertheless, the Tubridge™'s comprehensive product specifications could successfully address this challenge. Dr. Miranda opted for a 6.5mm x 45mm Tubridge™ stent and successfully implanted it into the patient's vessel. Leveraging the Tubridge™'s two radiopaque wires, the surgeon could discern, during the procedure, the stent's optimal apposition to the tortuous posterior circulation vessel wall. During post-release, conspicuous retention of contrast agent within the aneurysm underscored the stent's immediate and impactful blood flow redirection.

Tubridge™ offers comprehensive specifications, ranging from 2.5mm to 6.5mm in diameter and up to 45mm in length, addressing the majority of clinical aneurysm cases. These specifications mean that the Tubridge™ offers a superior option for larger or giant aneurysms. Moreover, braided with nitinol alloy wires, known for their superelasticity and ability to return to a predefined shape, Tubridge™ ensures excellent wall-apposition to tortuous intracranial vessels, facilitating endothelial cell growth and aneurysm healing.

From medical research to clinical application, Tubridge™ has redefined numerous pioneering standards within its category. Moving forward, MicroPort® NeuroTech™ remains dedicated to fostering deep collaborations with esteemed clinical experts worldwide, offering premium, comprehensive solutions to cerebrovascular patients worldwide.

About MicroPort® Neurotech™

MicroPort® NeuroTech™ (MicroPort NeuroTech Limited; HKEX: 2172) , an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment with solutions that currently support over 100 cerebrovascular stenting procedures every day. In the future, MicroPort® NeuroTech™ will continue investing more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro intervention solutions for doctors and patients.

More information is available at www.medneurotech.com